Typically each new entrant prices lower than the previous entrant to gain market share. The PBMs and retailers already buy the Mylan authorized generic, which

Typically each new entrant prices lower than the previous entrant to gain market share. The PBMs and retailers already buy the Mylan authorized generic, which is the same product and same price as the Teva product. So they have ability to tell Teva that they need to drop the price or they wont work w them. This is a typical dynamic in newly generic pharma markets